UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia

Leukemia & lymphoma, 2018-12, Vol.59 (12), p.2792-2800

2018

Volltextzugriff (PDF)

Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia

Leukemia & lymphoma, 2016-03, Vol.57 (3), p.501-502

2016

Volltextzugriff (PDF)

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL

Leukemia & lymphoma, 2023-12, Vol.64 (14), p.2306-2315

2023

Volltextzugriff (PDF)

Targeting malignant B cells with an immunotoxin against ROR1

mAbs, 2012-05, Vol.4 (3), p.349-361

2012

Volltextzugriff (PDF)

Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1

Leukemia & lymphoma, 2011-09, Vol.52 (9), p.1758-1769

2011

Volltextzugriff (PDF)

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy

Leukemia & lymphoma, 2019-01, Vol.60 (2), p.519-522

2019

Volltextzugriff (PDF)

Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors

Leukemia & lymphoma, 2020-08, Vol.61 (10), p.2375-2382

2020

Volltextzugriff (PDF)

Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma

Leukemia & lymphoma, 2021-07, Vol.62 (8), p.1828-1839

2021

Volltextzugriff (PDF)

CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage

Leukemia & lymphoma, 2022-03, Vol.63 (4), p.911-917

2022

Volltextzugriff (PDF)

Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features

Leukemia & lymphoma, 2020-11, Vol.61 (13), p.3177-3187

2020

Volltextzugriff (PDF)

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Leukemia & lymphoma, 2017-10, Vol.58 (10), p.2356-2362

2017

Volltextzugriff (PDF)

Richter Transformation to Hodgkin Lymphoma on Bruton Tyrosine Kinase Inhibitor Therapy

Leukemia & lymphoma, 2018-07, Vol.60 (2), p.519-522

2018

Volltextzugriff (PDF)

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study

Leukemia & lymphoma, 2021-07, Vol.62 (8), p.1816-1827

2021

Volltextzugriff (PDF)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Oncoimmunology, 2012-09, Vol.1 (6), p.959-961

2012

Volltextzugriff (PDF)

Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes

Leukemia & lymphoma, 2019-01, Vol.60 (1), p.242-245

2019

Volltextzugriff (PDF)

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies

Leukemia & lymphoma, 2014-09, Vol.55 (9), p.1968-1979

2014

Volltextzugriff (PDF)

Prognostic factors for risk-adapted therapy in chronic lymphocytic leukemia - The search continues

Leukemia & lymphoma, 2007-01, Vol.48 (8), p.1468-1469

2007

Volltextzugriff (PDF)

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF- kappa B pathways

Leukemia & lymphoma, 2008-04, Vol.49 (4), p.798-808

2008

Volltextzugriff (PDF)

Emerging therapeutic paradigms to target the dysregulated JAK/STAT pathways in hematological malignancies

Leukemia & lymphoma, 2014-02, Vol.55 (9), p.1968-1979

2014

Volltextzugriff (PDF)

Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia

Leukemia & lymphoma, 2013-03, Vol.54 (3), p.579-586

2013

Volltextzugriff (PDF)

Ibrutinib for the treatment of chronic lymphocytic leukemia

Expert opinion on orphan drugs, 2013-11, Vol.1 (11), p.925-933

2013

Volltextzugriff (PDF)

CD44 signaling via PI3K/AKT and MAPK/ERK pathways protects CLL cells from spontaneous and drug induced apoptosis through MCL-1

Leukemia & lymphoma, 2011-06, Vol.52 (9), p.1758-1769

2011

Volltextzugriff (PDF)

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

Leukemia & lymphoma, 2008-04, Vol.49 (4), p.798-808

2008

Volltextzugriff (PDF)

Soluble Cd52 levels predict time to first treatment for patients with chronic lymphocytic leukemia

LEUKEMIA & LYMPHOMA, 2015, Vol.56, p.134

2015

Volltextzugriff (PDF)

Structure and Function of the Amino Terminal Propeptide of Type I and III Collagen

Connective tissue research, 1982, Vol.10 (1), p.43-50

1982

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

KollektionNexis

KollektionTaylor & Francis Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(6)

Publikationsform

Artikel
(24)
Tagungsberichte
(1)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Leukemia & Lymphoma
(20)
Leukemia & Lymphoma/leukemia And Lymphoma
(12)
Connective Tissue Research
(1)
Expert Opinion On Orphan Drugs
(1)
Mabs
(1)
Oncoimmunology
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia

Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL

Targeting malignant B cells with an immunotoxin against ROR1

Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy

Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors

Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma

CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage

Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Richter Transformation to Hodgkin Lymphoma on Bruton Tyrosine Kinase Inhibitor Therapy

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies

Prognostic factors for risk-adapted therapy in chronic lymphocytic leukemia - The search continues

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF- kappa B pathways

Emerging therapeutic paradigms to target the dysregulated JAK/STAT pathways in hematological malignancies

Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia

Ibrutinib for the treatment of chronic lymphocytic leukemia

CD44 signaling via PI3K/AKT and MAPK/ERK pathways protects CLL cells from spontaneous and drug induced apoptosis through MCL-1

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

Soluble Cd52 levels predict time to first treatment for patients with chronic lymphocytic leukemia

Structure and Function of the Amino Terminal Propeptide of Type I and III Collagen

Aktive Filter

Suchergebnisse filtern